Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
One in two women with advanced ovarian cancer has an HRD-positive tumor
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
Lenalidomide is used to treat various types of cancers.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Subscribe To Our Newsletter & Stay Updated
